Obsessive Compulsive DisorderNCT01794156
Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder
A study testing Cognitive behavior therapy, Mindfulness-based stress reduction and Inference-based therapy in people with Obsessive Compulsive Disorder, run by Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal at 1 site in Canada.
Trial summary
Obsessional compulsive disorder (OCD) is a very debilitating psychiatric problem which affects around one million Canadians and their families. Obsessions are intense preoccupations about bad, harmful, dangerous, shocking or unlucky events which 'may' occur and which drive sufferers to perform time consuming and… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obsessive Compulsive Disorder
- What is being tested?
- Cognitive behavior therapy, Mindfulness-based stress reduction and Inference-based therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 111 participants
- Where
- 1 siteCanada
- Study dates
- Sep 2012to 30 Aug 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- primary diagnosis according to DSM-IV-TR criteria of OCD
- willingness to keep medication stable while participating in study
- willingness to undergo active psychological treatment
- willingness to undergo randomization into treatment modality
- fluency in either English or French.
- entry criteria do not exclude a secondary diagnosis on Axis I or II providing it does not require treatment or is deemed unlikely to significantly affect compliance with the current treatment plan.
- participants will also be screened on a brief battery of neuropsychological tests to ensure comparability of mental capacity between groups.
- no change in medication type or dose during the 12 weeks before treatment for antidepressants (4 weeks for anxiolytics. If antidepressant or medication as not been stable for at least 12 weeks, a stabilization period will be imposed. Other medication (e.g., anxiolytics) will have to be stable for at least four weeks.
Who cannot join
- presence of other principal axes 1 disorders requiring treatment
- evidence of suicidal intent
- evidence of current substance abuse
- evidence of current or past of suicidal intent
- evidence of current or past schizophrenia, bipolar disorder or organic mental disorder
Trial locations and contacts
1 site in 1 country.
Canada1 site
Centre de recherche de l'Institut universitaire en santé mentale de Montréal
Montreal, Quebec, H1N 3M5
About this study
Obsessional compulsive disorder (OCD) is a very debilitating psychiatric problem which affects around one million Canadians and their families. Obsessions are intense preoccupations about bad, harmful, dangerous, shocking or unlucky events which 'may' occur and which drive sufferers to perform time consuming and distressing compulsive rituals to prevent the possible event occurring. The current psychological treatment of choice is cognitive behavior (CBT) therapy which focuses on treating OCD by reducing obsessional anxiety about the likelihood and the consequences of the preoccupying event. A rival cognitive model termed the inference-based therapy (IBT), developed by the principal investigator and co-workers, considers that the OCD begins with the initial doubting inference 'maybe something is wrong' and focuses on changing the reasoning behind this doubting inference which often trumps the common sense conviction that there is no reason to doubt. This clinical trial randomly allocates participants to either IBT or CBT treatment condition or to a third generic mindfulness condition. The latter condition is a non-specific meditational-based training which has shown evidence of reducing stress and anxiety across a number of psychiatric problems including OCD. Two hundred and forty people will be recruited over a 5-year period from two principal sites (Montreal and Gatineau/Ottawa) with which the principal investigator and co-investigators have clinical links. Therapy will be administered by trained professionals following a treatment manual specific to each approach. The therapy will last a maximum of six months or until the point when the person achieves a non-clinical status. The patients will be assessed pre, post, and at six months following treatment on standard evaluation instruments as well as on subjective measures. We expect the IBT to be superior in terms of number of participants responding to treatment, rapidity of improvement and gains at follow-up.
Read the detailed description
Obsessive compulsive disorder (OCD) affects 1-3% of the population and is the fourth most common mental disorder. It is characterized by a preoccupying obsessional doubt that harm, illness, disorder or bad luck, will occur if compulsive actions are not carried out to neutralize the risk. Treatments of choice include pharmacotherapy and cognitive behavior therapy (CBT) either alone or in combination. Although these interventions are clinically effective, they usually do not reduce the obsessions to a sub-clinical level. There is a risk of relapse and even so a sizeable minority of people with OCD refuse or abandon treatment, and some specific subtypes of OCD show no or minimal response. CBT-as-usual, involves principally the administration of exposure and response prevention (E/RP). A cognitive psycho-education element may by added in line with current cognitive thinking that it is the appraisal the person attributes to the initial intrusive thought with engenders obsessional distress. Such cognitive treatment will focus on modifying the anxiety and beliefs about consequences following on from the initial obsessional preoccupation. A competing cognitive model termed the inference-based approach (IBA) developed by the principal investigator and co-workers offers an account of obsessions which focuses on the reasoning producing the initial obsessional doubt as the source of the OCD. In this model the obsessing begins at the point where the person crosses over from reality into the initial obsessional doubt since the doubt is not based on real perception but on a subjective narrative misleading the person to infer doubt where no doubt is required. Over the last 10 years, experimental, clinical and psychometric research studies (independently replicated) have supported the essential claims of the IBA and have led to development of inference-based therapy (IBT). A small scale randomized clinical trial, and clinical case studies have established IBT as a 'promising' intervention (according to American Psychological Association criteria) and shown that IBT seems to offer advantages over conventional CBT, particularly for treatment-resistant cases who over-invest in their obsessional convictions. The current randomized clinical trial will compare IBT to CBT as usual, and to a third active control condition of mindfulness. Mindfulness is a generic treatment shown effective in a range of psychiatric problems which seeks to calm thoughts by redirecting mental focus through meditative distancing. The mindfulness condition is a non-specific cognitive control for any confounding effect of mood change on symptom relief. CBT follows an 'appraisal' model either through restructuring appraisals and beliefs about the obsession or by de-dramatizing anxious expectations through exposure and reality testing (combined with E/RP). IBT seeks to change the reasoning leading up to the initial inference of doubt on the principle that eliminating the doubt logically and necessarily eliminates all anticipated consequences and accompanying obsessional anxiety. All three treatments will be manualized and administered by experienced professional therapists supervised by a co-investigator with an allegiance to one of the three approaches. The three treatment models operate on distinct processes and on separable stages of the obsessional chain, so therapy components will not overlap. The principal sites chosen will be Montreal Louis-H. Lafontaine Hospital and Gatineau Pierre-Janet Hospital. A total of 80 participants will be recruited over a five-year period into each treatment modality, giving a total of 240, which will permit robust conclusions even with weak effect sizes. Outcome evaluators will be blind to treatment modality and independent of therapists. All therapy will be delivered on an individual weekly basis until significant clinical improvement or up to a maximum of 26 weeks with a 6-month follow-up post-treatment. All parameters of treatment delivery will be identical across treatments. All sessions will be audio recorded and treatment integrity will be rated independently. Outcome measures will be standard DSM-IV based clinical diagnostic scales and also psychosocial measures of end-point functioning across life domains. Treatment process variables will be continuously monitored. Refusal and attrition are calculated at 16% and analysis will include intention to treat. The hypotheses are that: (1) all treatments will be effective in improving mood and reducing symptoms; (2) the IBT will be superior in terms of: (a) its consistent impact over all types of OCD; (b) its lower rate of relapse. The RCT will be the first of its kind in comparing these three active treatments and will impact on treatment of choice for OCD.
- Conditions
- Obsessive Compulsive Disorder
- Being tested
- Cognitive behavior therapy, Mindfulness-based stress reduction, Inference-based therapy
- Keywords
- Inference-based therapy, Cognitive behavior therapy, Obsessive compulsive disorder, Randomized clinical trial
- Medical subject headings
- Obsessive-Compulsive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive behavior therapyBehavioural
Mindfulness-based stress reductionBehavioural
Inference-based therapyBehavioural
| Study group | Role | What they receive |
|---|---|---|
| Cognitive behavior therapy | Active comparator | 1. The cognitive-behavioral model is presented and individualized.
2. Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs
3. Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.
4. Combined phase: continues ERP while making explicit links to the cognitive targets.
5. Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues. Receives: Behavioral: Cognitive behavior therapy |
| Mindfulness-based stress reduction (MBSR) | Active comparator | The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience. Receives: Behavioral: Mindfulness-based stress reduction |
| Inference-based therapy | Experimental | The inference-based therapy will be delivered in 10-step
The client will:
* learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt
* learn why this doubt is 100% irrelevant here and now
* learn the inferential confusion process
* have to recognize that the doubt originates from him/her
* have to identify/describe the narrative leading him/her to the doubt
* have to identify the cross-over point when he/she leaves reality
* learn to be aware of the reasoning devices
* learn how personal themes dictate the idiosyncratic nature of the person's obsession
* explore and reinforced an alternative self-view
* be trained to use properly his/her senses in the face of obsessional triggers situations Receives: Behavioral: Inference-based therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
The Yale-Brown Obsessive-Compulsive Scale (translation) is the instrument of choice to assess obsessive compulsive symptoms and severity.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Secondary outcomes (13)
Vancouver Obsessional Compulsive Inventory (VOCI)
The Vancouver Obsessional Compulsive Inventory (VOCI)(Translation) to assess a broad spectrum of OCD symptoms and associated personality characteristics.It is a 55-item self-report measure to assess a broad spectrum of OCD symptoms and associated personality characteristics.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Obsessive Beliefs Questionnaire (OBQ-44)
The Obsessive Beliefs Questionnaire (OBQ-44) is a 44-item measure developed by the Obsessive Compulsive Cognitions Working Group between 1995 and 1998. The OBQ consist in three twinned domains based on the working group consensus (over-responsibility/over-estimation of threat, intolerance of uncertainty/over-importance of thought, control of thoughts/perfectionism).
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Beck Depression Inventory (BDI)
The Beck Depression Inventory (BDI) (Translation) is a standard 21-item measure to assess depressive symptoms.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI)(Translation) is a standard 21-item anxiety symptom checklist rating anxiety symptom intensity for the last week on a 0-3 scale.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Over-Values Ideas Scale (OVIS)
Over-Valued Ideas Scale (OVIS)(Translation)is a 11-item clinician-rated scale measuring degree of conviction, insight, justification and actions following from belief.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Inferential Confusion Questionnaire (ICQ)
The ICQ was originally developed in French and is a 30-item questionnaire.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Semi-structured interview to assess primary inference process
Primary inference processes will be rated by semi-structured interview for each obsession on a clinical scale, and daily by the participant, in the daily diary. Strength is rated 0-100 in accordance with how probable the participant considers the primary belief whether it is a doubt "maybe the door isn't locked properly".
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Mindful Attention Awareness Scale (MAAS)
The MAAS is a 15-item questionnaire which measures the tendency to be attentive and aware of present moment experience in everyday life and does not require extensive experience with mindfulness. It is uni-dimensional and is appropriate for exploring changes in awareness and attention associated with mindfulness-based stress reduction (MBSR) and is predictive of mood and adaptive regulation.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Global Assessment of Functioning (GAF) scale (DSM-IV, Axis V)
The GAF is a standard DSM measure of adaptation and functioning scored from 0-100.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Systematic Quality of Life Inventory
The Systematic Quality of Life Inventory measure 30 life domains, using three subscales: actual state, goal state and the difference between actual and desired goals of quality of life.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Life Experience Survey
The Life Experience Survey measures negative and positive life events and their impact over 57 life domains.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Social Support Questionnaire
The Social Support Questionnaire has two scales measuring amount and degree of satisfaction with social support.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Social Self-esteem Inventory
The Social Self-esteem Inventory measures agreement on 30 self-statements.
Measured: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2013 (estimated)
- Study startSep 2012
- Primary completionAug 2019
- Study completion30 Aug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obsessive Compulsive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 111 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, Frederick Aardema, Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
- Investigators
- Frederick Aardema, Ph. D., Principal investigator, Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01794156
- Sponsor's protocol ID
- 119587
- Status last verified
- Oct 2021
- First submitted
- 7 Feb 2013
- Last updated
- 28 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
Publications
Ouellet-Courtois C, Bouchard S, Giguere CE, Koszycki D, Lavoie ME, Aardema F. Cognitive mechanisms of change in OCD: Inferential confusion, obsessive beliefs, and mindfulness across three randomized treatments. Behav Res Ther. 2026 Jun;201:105022. doi: 10.1016/j.brat.2026.105022. Epub 2026 Mar 29.
PubMed 41930538
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder
- ClinicalTrials.gov ID
- NCT01794156
- Acronym / sponsor ID
- 119587
- Conditions
- Obsessive Compulsive Disorder
- Keywords
- Inference-based therapy, Cognitive behavior therapy, Obsessive compulsive disorder, Randomized clinical trial
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 111 participants (actual)
- Lead sponsor
- Centre de Recherche de l'Institut Universitaire en santé Mentale de MontréalUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- Sep 2012
- Primary completion
- Aug 2019 (actual)
- Study completion
- 30 Aug 2019 (actual)
- First posted
- 18 Feb 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obsessional compulsive disorder (OCD) is a very debilitating psychiatric problem which affects around one million Canadians and their families. Obsessions are intense preoccupations about bad, harmful, dangerous, shocking or unlucky events which 'may' occur and which drive sufferers to perform time consuming and distressing compulsive rituals to prevent the possible event occurring. The current psychological treatment of choice is cognitive behavior (CBT) therapy which focuses on treating OCD by reducing obsessional anxiety about the likelihood and the consequences of the preoccupying event. A rival cognitive model termed the inference-based therapy (IBT), developed by the principal investigator and co-workers, considers that the OCD begins with the initial doubting inference 'maybe something is wrong' and focuses on changing the reasoning behind this doubting inference which often trumps the common sense conviction that there is no reason to doubt. This clinical trial randomly allocates participants to either IBT or CBT treatment condition or to a third generic mindfulness condition. The latter condition is a non-specific meditational-based training which has shown evidence of reducing stress and anxiety across a number of psychiatric problems including OCD. Two hundred and forty people will be recruited over a 5-year period from two principal sites (Montreal and Gatineau/Ottawa) with which the principal investigator and co-investigators have clinical links. Therapy will be administered by trained professionals following a treatment manual specific to each approach. The therapy will last a maximum of six months or until the point when the person achieves a non-clinical status. The patients will be assessed pre, post, and at six months following treatment on standard evaluation instruments as well as on subjective measures. We expect the IBT to be superior in terms of number of participants responding to treatment, rapidity of improvement and gains at follow-up.
Detailed description
Obsessive compulsive disorder (OCD) affects 1-3% of the population and is the fourth most common mental disorder. It is characterized by a preoccupying obsessional doubt that harm, illness, disorder or bad luck, will occur if compulsive actions are not carried out to neutralize the risk. Treatments of choice include pharmacotherapy and cognitive behavior therapy (CBT) either alone or in combination. Although these interventions are clinically effective, they usually do not reduce the obsessions to a sub-clinical level. There is a risk of relapse and even so a sizeable minority of people with OCD refuse or abandon treatment, and some specific subtypes of OCD show no or minimal response. CBT-as-usual, involves principally the administration of exposure and response prevention (E/RP). A cognitive psycho-education element may by added in line with current cognitive thinking that it is the appraisal the person attributes to the initial intrusive thought with engenders obsessional distress. Such cognitive treatment will focus on modifying the anxiety and beliefs about consequences following on from the initial obsessional preoccupation. A competing cognitive model termed the inference-based approach (IBA) developed by the principal investigator and co-workers offers an account of obsessions which focuses on the reasoning producing the initial obsessional doubt as the source of the OCD. In this model the obsessing begins at the point where the person crosses over from reality into the initial obsessional doubt since the doubt is not based on real perception but on a subjective narrative misleading the person to infer doubt where no doubt is required. Over the last 10 years, experimental, clinical and psychometric research studies (independently replicated) have supported the essential claims of the IBA and have led to development of inference-based therapy (IBT). A small scale randomized clinical trial, and clinical case studies have established IBT as a 'promising' intervention (according to American Psychological Association criteria) and shown that IBT seems to offer advantages over conventional CBT, particularly for treatment-resistant cases who over-invest in their obsessional convictions. The current randomized clinical trial will compare IBT to CBT as usual, and to a third active control condition of mindfulness. Mindfulness is a generic treatment shown effective in a range of psychiatric problems which seeks to calm thoughts by redirecting mental focus through meditative distancing. The mindfulness condition is a non-specific cognitive control for any confounding effect of mood change on symptom relief. CBT follows an 'appraisal' model either through restructuring appraisals and beliefs about the obsession or by de-dramatizing anxious expectations through exposure and reality testing (combined with E/RP). IBT seeks to change the reasoning leading up to the initial inference of doubt on the principle that eliminating the doubt logically and necessarily eliminates all anticipated consequences and accompanying obsessional anxiety. All three treatments will be manualized and administered by experienced professional therapists supervised by a co-investigator with an allegiance to one of the three approaches. The three treatment models operate on distinct processes and on separable stages of the obsessional chain, so therapy components will not overlap. The principal sites chosen will be Montreal Louis-H. Lafontaine Hospital and Gatineau Pierre-Janet Hospital. A total of 80 participants will be recruited over a five-year period into each treatment modality, giving a total of 240, which will permit robust conclusions even with weak effect sizes. Outcome evaluators will be blind to treatment modality and independent of therapists. All therapy will be delivered on an individual weekly basis until significant clinical improvement or up to a maximum of 26 weeks with a 6-month follow-up post-treatment. All parameters of treatment delivery will be identical across treatments. All sessions will be audio recorded and treatment integrity will be rated independently. Outcome measures will be standard DSM-IV based clinical diagnostic scales and also psychosocial measures of end-point functioning across life domains. Treatment process variables will be continuously monitored. Refusal and attrition are calculated at 16% and analysis will include intention to treat. The hypotheses are that: (1) all treatments will be effective in improving mood and reducing symptoms; (2) the IBT will be superior in terms of: (a) its consistent impact over all types of OCD; (b) its lower rate of relapse. The RCT will be the first of its kind in comparing these three active treatments and will impact on treatment of choice for OCD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cognitive behavior therapy | Active comparator | Behavioral: Cognitive behavior therapy1. The cognitive-behavioral model is presented and individualized. 2. Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs 3. Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate. 4. Combined phase: continues ERP while making explicit links to the cognitive targets. 5. Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues. |
| Mindfulness-based stress reduction (MBSR) | Active comparator | Behavioral: Mindfulness-based stress reductionThe entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience. |
| Inference-based therapy | Experimental | Behavioral: Inference-based therapyThe inference-based therapy will be delivered in 10-step The client will: * learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt * learn why this doubt is 100% irrelevant here and now * learn the inferential confusion process * have to recognize that the doubt originates from him/her * have to identify/describe the narrative leading him/her to the doubt * have to identify the cross-over point when he/she leaves reality * learn to be aware of the reasoning devices * learn how personal themes dictate the idiosyncratic nature of the person's obsession * explore and reinforced an alternative self-view * be trained to use properly his/her senses in the face of obsessional triggers situations |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- primary diagnosis according to DSM-IV-TR criteria of OCD
- willingness to keep medication stable while participating in study
- willingness to undergo active psychological treatment
- willingness to undergo randomization into treatment modality
- fluency in either English or French.
Key exclusion criteria (5 listed)
- presence of other principal axes 1 disorders requiring treatment
- evidence of suicidal intent
- evidence of current substance abuse
- evidence of current or past of suicidal intent
- evidence of current or past schizophrenia, bipolar disorder or organic mental disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive behavior therapy | Behavioural | Cognitive behavior therapy |
| Mindfulness-based stress reduction | Behavioural | Mindfulness-based stress reduction (MBSR) |
| Inference-based therapy | Behavioural | Inference-based therapy |
Primary outcome
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
The Yale-Brown Obsessive-Compulsive Scale (translation) is the instrument of choice to assess obsessive compulsive symptoms and severity.
13 secondary outcomes
Vancouver Obsessional Compulsive Inventory (VOCI)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Obsessive Beliefs Questionnaire (OBQ-44)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Beck Depression Inventory (BDI)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Beck Anxiety Inventory (BAI)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Over-Values Ideas Scale (OVIS)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Inferential Confusion Questionnaire (ICQ)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Semi-structured interview to assess primary inference process
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Mindful Attention Awareness Scale (MAAS)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Global Assessment of Functioning (GAF) scale (DSM-IV, Axis V)
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Systematic Quality of Life Inventory
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Life Experience Survey
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Social Support Questionnaire
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Social Self-esteem Inventory
Time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2021.
- Derived from this study: PubMed 41930538Ouellet-Courtois C, Bouchard S, Giguere CE, Koszycki D, Lavoie ME, Aardema F. Cognitive mechanisms of change in OCD: Inferential confusion, obsessive beliefs, and mindfulness across three randomized treatments. Behav Res Ther. 2026 Jun;201:105022. doi: 10.1016/j.brat.2026.105022. Epub 2026 Mar 29.
Related trials for Obsessive Compulsive Disorder
Enrolling by invitation
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder: A Randomized Controlled Trial
Obsessive - Compulsive Disorder, Family Accommodation
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Frederick Aardema, Ph. D. principal investigator
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive behavior therapy, Mindfulness-based stress reduction and Inference-based therapy in people with Obsessive Compulsive Disorder, run by Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (time frame: Baseline, change after 26 weeks of treatment, change after 6-month follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01794156, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2021.